Liposome-mediated delivery of a ruthenium-based metallodrug to overcome cisplatin resistance in osteosarcoma.

Drug Deliv · 2026 · PMC13169444 · PMID 42116576

Europe PMC DOI

hedged sentence

0.0660

closest p · 1.3× alpha

0.0660

boldest claim

The sentences

did not reach statistical significancep = 0.066so close (0.05 < p ≤ 0.1)

Interestingly, there was a trend toward increased antitumor efficacy of the liposomal formulation of Ru3 compared with the free metallodrug, although this did not reach statistical significance ( p = 0.066).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.